A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer

BACKGROUND: Breast cancer remains a leading cause of cancer death worldwide. There is evidence that immunotherapy may play a role in the eradication of residual disease. Peptide vaccines for immunotherapy are capable of durable immune memory, but vaccines alone have shown sparse clinical activity ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Dillon, Patrick M., Petroni, Gina R., Smolkin, Mark E., Brenin, David R., Chianese-Bullock, Kimberly A., Smith, Kelly T., Olson, Walter C., Fanous, Ibrahim S., Nail, Carmel J., Brenin, Christiana M., Hall, Emily H., Slingluff, Craig L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697108/
https://www.ncbi.nlm.nih.gov/pubmed/29157306
http://dx.doi.org/10.1186/s40425-017-0295-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697108/
https://www.ncbi.nlm.nih.gov/pubmed/29157306
http://dx.doi.org/10.1186/s40425-017-0295-5

Ejemplares similares